Aclaris Therapeutics
ACRS
115 hedge funds and large institutions have $883M invested in Aclaris Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 48 increasing their positions, 27 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
89% more call options, than puts
Call options by funds: $541K | Put options by funds: $286K
78% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 27
5% more funds holding
Funds holding: 110 → 115 (+5)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
1.82% less ownership
Funds ownership: 96.85% → 95.03% (-1.8%)
14% less capital invested
Capital invested by funds: $1.02B → $883M (-$140M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$36.2M |
| 2 |
O
OrbiMed
New York
|
+$10.4M |
| 3 |
BlackRock
New York
|
+$9.57M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$8.71M |
| 5 |
JP Morgan Chase
New York
|
+$5.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.61M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$5.09M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.1M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.61M |
ACRS Hedge Fund Activity: Q2 2022 in Review
115 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2022, worth a combined $883M — down 14% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ACRS positions and 8 closed out — a net gain of 8 holders — while 48 added to existing stakes and 27 trimmed.
The largest buyer was RA Capital Management, adding an estimated $36.2M. The largest seller was Wellington Management Group, cutting an estimated $11.6M.
- 115 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2022, up from 110 in Q1 2022.
- Funds reported $883M of Aclaris Therapeutics stock for Q2 2022, down 14% quarter-over-quarter.
- 16 funds opened new Aclaris Therapeutics positions in Q2 2022 and 8 closed out, a net change of +8 holders.
- The largest Aclaris Therapeutics buyer in Q2 2022 was RA Capital Management, an estimated $36.2M added.
- The largest Aclaris Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $11.6M sold.
Based on aggregated 13F filings for Q2 2022.